The FDA approval for Eli Lilly’s Alzheimer’s drug has been delayed.
The pharmaceutical industry is abuzz with news of a potential breakthrough in the treatment of Alzheimer’s disease. Eli Lilly & Co. recently announced that its experimental drug, donanemab, showed promising results in slowing the progression … Read more
